09 December 2024 : Clinical Research
Shiga Toxin-Producing E. coli and Hemolytic Uremic Syndrome: A Study of the 2022 Outbreak in Turkey
Oğuzhan Zengin
ABCDEFG 1*, Burak Göre ABCDEFG 1, Oğuz Öztürk ABCDEFG 2, Muhammet Göv ABCDEFG 1, Enes Seyda Şahiner ABCDEFG 1, Osman İnan ABCDEFG 1, Emra Asfuroğlu Kalkan ABCDEFG 1, Şimal Kösal Cevher ABCDEFG 3, Ahmet Kürşad Güneş ABCDEFG 4, Gülsüm Özet ABCDEFG 5, İhsan Ateş ABCDEFG 1
DOI: 10.12659/MSM.946033
Med Sci Monit 2024; 30:e946033
Table 1 Evaluation of demographic characteristics, treatments, and extrarenal findings at admission.
| Age | 55 (22–81) |
| Male | 4 (19.05%) |
| Female | 17 (80.95%) |
| Oliguria | 16 (76.1%) |
| Hemorrhagic diarrhea | 10 (47.6%) |
| Total length of hospital stay | 20.71±11.49 17 (2–56) |
| Eculizumab | 4 (19.05%) |
| Plasmapheresis | 7 (33.33%) |
| Hemodialysis | 10 (47.67%) |
| Antibiotic | 8 (38.10%) |
| Cardiogenic involvement | 1 (4.76%) |
| Neurogenic involvement | 5 (23.81%) |
| Abdominal involvement | 21 (100.00%) |
| Pulmonary involvement | 19 (90.48%) |